All In Biotech

Drug Trial Radar · NCT01782326

QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)

A 52-week Treatment, Multi-center, Randomized, Double-blind, Double Dummy, Parallel-group, Active Controlled Study to Compare the Effect of QVA149 (Indacaterol Maleate / Glycopyrronium Bromide) With Salmeterol/Fluticasone on the Rate of Exacerbations in Subjects With Moderate to Very Severe COPD. (FLAME).

Last checked: Nov 19, 2026Latest source record: May 16, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,362 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,362

Actual

Start

Jul 2013

Primary completion

Sep 2015

Study completion Sep 2015

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Feb 1, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess the efficacy, safety and tolerability of QVA149 in patients with moderate to very severe COPD.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

  • QVA149Drug

    QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept 1 SDDPI.

  • Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)Drug

    Salmeterol/fluticasone dry inhalation powder delivered via the Accuhaler device.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of COPD ExacerbationsTime frame: 52 weeks

Locations

499 sites in 43 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Ciudad de Buenos Aires, Argentina, Argentina

  • Novartis Investigative Site

    Buenos Aires, Buenos Aires, Argentina

  • Novartis Investigative Site

    Buenos Aires, Buenos Aires, Argentina

  • Novartis Investigative Site

    Caba, Buenos Aires, Argentina

  • Novartis Investigative Site

    Caba, Buenos Aires, Argentina

  • Novartis Investigative Site

    Caba, Buenos Aires, Argentina

  • Novartis Investigative Site

    Caba, Buenos Aires, Argentina

  • Novartis Investigative Site

    Caba, Buenos Aires, Argentina

  • Novartis Investigative Site

    Caba, Buenos Aires, Argentina

  • Novartis Investigative Site

    Caba, Buenos Aires, Argentina

  • Novartis Investigative Site

    Caba, Buenos Aires, Argentina

  • Novartis Investigative Site

    Lanus, Buenos Aires, Argentina

  • Novartis Investigative Site

    Mar del Plata, Buenos Aires, Argentina

  • Novartis Investigative Site

    Mar del Plata, Buenos Aires, Argentina

  • Novartis Investigative Site

    Mar del Plata, Buenos Aires, Argentina

  • Novartis Investigative Site

    Buenos Aires, Buenos Aires F.D., Argentina

  • Novartis Investigative Site

    Concepción del Uruguay, Entre Ríos Province, Argentina

  • Novartis Investigative Site

    Mendoza, Mendoza Province, Argentina

  • Novartis Investigative Site

    Mendoza, Mendoza Province, Argentina

  • Novartis Investigative Site

    Salta, Salta Province, Argentina

  • Novartis Investigative Site

    Rosario, Santa Fe Province, Argentina

  • Novartis Investigative Site

    Rosario, Santa Fe Province, Argentina

  • Novartis Investigative Site

    Santa Fe, Santa Fe Province, Argentina

  • Novartis Investigative Site

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Novartis Investigative Site

    San Miguel de Tucumán, Tucumán Province, Argentina

  • Novartis Investigative Site

    Salzburg, Austria

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Feldbach, Austria, Austria

  • Novartis Investigative Site

    Feldkirch, Austria, Austria

  • Novartis Investigative Site

    Graz, Austria, Austria

  • Novartis Investigative Site

    Grieskirchen, Austria, Austria

  • Novartis Investigative Site

    Linz, Austria, Austria

  • Novartis Investigative Site

    Thalheim bei Wels, Austria, Austria

  • Novartis Investigative Site

    Wels, Austria, Austria

  • Novartis Investigative Site

    Innsbruck, Tyrol, Austria

  • Novartis Investigative Site

    Aalst, Belgium

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Brussels, Belgium

Showing 40 of 499 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.